Ashton Thomas Securities LLC Boosts Stock Position in Thermo Fisher Scientific Inc. $TMO

Ashton Thomas Securities LLC increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 196.0% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,621 shares of the medical research company’s stock after buying an additional 3,722 shares during the quarter. Ashton Thomas Securities LLC’s holdings in Thermo Fisher Scientific were worth $2,726,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the stock. Jacobsen Capital Management raised its holdings in shares of Thermo Fisher Scientific by 6.4% during the 3rd quarter. Jacobsen Capital Management now owns 1,687 shares of the medical research company’s stock worth $818,000 after acquiring an additional 101 shares during the period. Arcadia Investment Management Corp MI increased its position in Thermo Fisher Scientific by 3.2% during the third quarter. Arcadia Investment Management Corp MI now owns 33,232 shares of the medical research company’s stock worth $16,118,000 after purchasing an additional 1,030 shares during the last quarter. WealthPLAN Partners LLC raised its stake in Thermo Fisher Scientific by 6.0% during the third quarter. WealthPLAN Partners LLC now owns 4,234 shares of the medical research company’s stock worth $2,054,000 after purchasing an additional 241 shares during the period. Retirement Planning Group LLC acquired a new position in Thermo Fisher Scientific in the 3rd quarter valued at about $267,000. Finally, Exencial Wealth Advisors LLC grew its stake in shares of Thermo Fisher Scientific by 26.9% in the 3rd quarter. Exencial Wealth Advisors LLC now owns 37,678 shares of the medical research company’s stock valued at $18,274,000 after buying an additional 7,994 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently commented on TMO. Leerink Partners upped their price objective on Thermo Fisher Scientific from $545.00 to $580.00 and gave the company an “outperform” rating in a report on Wednesday, October 22nd. Hsbc Global Res raised Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research note on Monday, December 1st. KeyCorp raised Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price objective for the company in a research report on Sunday, December 7th. Wells Fargo & Company upped their target price on shares of Thermo Fisher Scientific from $635.00 to $675.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Finally, Wall Street Zen cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Saturday. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $625.47.

Insider Activity

In related news, EVP Frederick M. Lowery sold 6,913 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $597.68, for a total transaction of $4,131,761.84. Following the sale, the executive vice president directly owned 14,367 shares in the company, valued at approximately $8,586,868.56. This represents a 32.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Michel Lagarde sold 32,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $583.39, for a total transaction of $18,668,480.00. Following the completion of the transaction, the chief operating officer owned 65,480 shares of the company’s stock, valued at $38,200,377.20. This represents a 32.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 149,271 shares of company stock worth $86,507,282 over the last three months. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Down 1.4%

Shares of NYSE:TMO opened at $606.75 on Wednesday. The firm’s 50-day moving average is $583.18 and its two-hundred day moving average is $520.93. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $628.08. The firm has a market capitalization of $227.96 billion, a PE ratio of 35.05, a price-to-earnings-growth ratio of 4.05 and a beta of 0.91.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. The firm had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.94%.

Thermo Fisher Scientific announced that its Board of Directors has initiated a share buyback program on Thursday, November 6th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to purchase up to 2.4% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.